Table 3. Summary ORs (95% CI) categorized by ethnicity for the XPG Asp1104His and XPF Arg415Gln polymorphisms under different genetic models and cancer type. 1 .
| Ethnicity | Cancer type | N | Recessive model | Dominant model | Homozygote | Heterozygote | Additive model | |||||
| OR (95%CI) | Ph/I2 (%) | OR (95%CI) | Ph/I2 (%) | OR (95%CI) | Ph/I2 (%) | OR (95%CI) | Ph/I2 (%) | OR (95%CI) | Ph/I2 (%) | |||
| XPG Asp1104His | ||||||||||||
| Caucasian | Bladder cancer | 4 (2111/2060) | 0.84 (0.50–1.41)* | 0.078/56.0 | 0.99 (0.88–1.12) | 0.673/0.0 | 0.85 (0.51–1.42)* | 0.090/53.8 | 1.01 (0.89–1.15) | 0.688/0.0 | 0.98 (0.89–1.08) | 0.433/0.0 |
| Breast cancer | 6 (3111/3675) | 1.07 (0.86–1.32) | 0.221/28.6 | 1.07 (0.92–1.24)* | 0.065/51.8 | 1.08 (0.87–1.34) | 0.215/29.3 | 1.07 (0.91–1.26)* | 0.048/55.2 | 1.03 (0.95–1.12) | 0.113/43.8 | |
| Colorectal cancer | 4 (1051/1240) | 0.92 (0.57–1.48) | 0.262/25.2 | 1.11 (0.93–1.31) | 0.688/0.0 | 0.97 (0.59–1.58) | 0.372/0.0 | 1.20 (0.96–1.49) | 0.397/0.0 | 1.10 (0.93–1.31) | 0.940/0.0 | |
| Glioma | 3 (1719/2789) | 0.98 (0.81–1.19) | 0.262/25.3 | 1.03 (0.90–1.18) | 0.984/0.0 | 0.97 (0.78–1.19) | 0.322/0.0 | 1.06 (0.92–1.23) | 0.810/0.0 | 1.01 (0.91–1.12) | 0.774/0.0 | |
| HNC | 3 (1412/1925) | 0.71 (0.51–0.97) | 0.271/23.5 | 1.04 (0.90–1.20) | 0.739/0.0 | 0.73 (0.53–1.02) | 0.378/0.0 | 1.10 (0.95–1.28) | 0.543/0.0 | 0.98 (0.87–1.10) | 0.819/0.0 | |
| Melanoma | 8 (5297/7072) | 0.87 (0.69–1.12)* | 0.050/50.3 | 0.97 (0.90–1.04) | 0.762/0.0 | 0.87 (0.68–1.11)* | 0.059/48.4 | 0.98 (0.90–1.06) | 0.854/0.0 | 0.97 (0.91–1.03) | 0.336/12.1 | |
| Other cancer | 5 (1133/1627) | 1.21 (0.86–1.70) | 0.345/10.7 | 1.04 (0.89–1.22) | 0.599/0.0 | 1.20 (0.85–1.69) | 0.422/0.0 | 1.02 (0.86–1.20) | 0.522/0.0 | 1.06 (0.93–1.21) | 0.501/0.0 | |
| Asian | Lung cancer | 3 (1428/1105) | 1.07 (0.88–1.29) | 0.673/0.0 | 1.27 (1.06–1.51) | 0.133/50.5 | 1.28 (1.02–1.60) | 0.516/0.0 | 1.35 (0.93–1.96)* | 0.073/61.9 | 1.13 (1.01–1.26) | 0.559/0.0 |
| Other cancer | 4 (1031/1368) | 1.04 (0.85–1.28) | 0.350/8.6 | 1.14 (0.82–1.60)* | 0.029/66.9 | 1.12 (0.88–1.43) | 0.176/39.3 | 1.15 (0.79–1.67)* | 0.017/70.7 | 1.03 (0.92–1.16) | 0.187/37.5 | |
| XPF Arg415Gln | ||||||||||||
| Caucasian | Breast cancer | 7 (3258/3729) | 2.17 (0.68–6.88)* | 0.022/61.9 | 1.10 (0.96–1.25) | 0.396/3.9 | 2.07 (0.56–7.62)* | 0.008/68.2 | 1.05 (0.89–1.23) | 0.522/0.0 | 1.10 (0.89–1.35)* | 0.094/46.8 |
| HNC | 4 (1643/2156) | 1.47 (0.72–2.98) | 0.364/5.8 | 1.04 (0.88–1.23) | 0.359/6.9 | 1.48 (0.73–3.00) | 0.370/4.5 | 1.02 (0.86–1.21) | 0.323/13.9 | 1.05 (0.90–1.23) | 0.302/17.7 | |
| Colorectal cancer | 3 (798/781) | 1.26 (0.40–4.01) | – | 0.99 (0.76–1.30) | 0.519/0.0 | 1.28 (0.40–4.07) | – | 0.97 (0.69–1.36) | 0.271/17.6 | 1.00 (0.74–1.36) | 0.253/23.5 | |
| Other cancer | 4 (4215/5095) | 1.20 (0.77–1.87) | 0.168/40.6 | 0.95 (0.85–1.06) | 0.549/0.0 | 1.19 (0.77–1.86) | 0.184/38.0 | 0.94 (0.84–1.05) | 0.406/0.0 | 0.96 (0.87–1.07) | 0.666/0.0 | |
1
All summary ORs were calculated using fixed-effects models. In the case of significant heterogeneity (indicated by *), ORs were calculated using random-effects models. The bold values indicate that the results are statistically significant.